⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19305280 | 1.00 | ARG2 (0.53) | — | |
| SCHEMBL24323664 | 1.00 | — | — | |
| SCHEMBL2972023 | 1.00 | — | — | |
| SCHEMBL16274192 | 0.86 | DDAH1 (0.55) | — | |
| SCHEMBL1803840 | 0.86 | DDAH1 (0.55) | — | |
| SCHEMBL19305284 | 0.86 | DDAH1 (0.55) | — | |
| SCHEMBL4260017 | 0.85 | GSR (0.57) | — | |
| SCHEMBL1272453 | 0.85 | GSR (0.57) | — | |
| SCHEMBL1272384 | 0.85 | GSR (0.57) | — | |
| SCHEMBL17131071 | 0.83 | GSR (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725480-A1 | RAMAN SPECTROSCOPY FOR PERSONALIZED CANCER MEDICINE | Endress+Hauser Process Analysis Support SARL (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4520324-A1 | COMPOSITION COMPRISING A TAURINE TRANSPORTER (TAUT) INHIBITOR AND 5-AMINOLEVULINIC ACID (5-ALA), ITS USE IN TREATING CANCER CELL TUMORS, AND ANALYSIS OF THE EFFECTIVENESS OF THE COMPOSITION | Endress+Hauser Process Analysis Support SARL (FR) | 2025-03-12 | — | — | EP | claimed |
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | claimed |
| EP-4378536-A2 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| CN-117866036-A | Method for preparing polysaccharide conjugate vaccine based on thiol click chemistry and product thereof | 成都康华生物制品股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| EP-3169403-B1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-02-14 | — | — | EP | claimed |
| CN-110093811-B | Surface sizing agent with storage stability and strong adhesion and preparation method thereof | 南昌市龙然实业有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-108719645-B | Creep feed mate | 宁波科瑞特动物药业有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-109626860-B | Preparation method of block viscosity-reducing concrete admixture | 科之杰新材料集团有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-109790261-B | Preparation method of block slow-release concrete admixture | 科之杰新材料集团有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-109535347-B | Preparation method of block water-retaining concrete admixture | 科之杰新材料集团有限公司 | 2021-01-22 | — | — | CN | claimed |
| WO-2020132809-A1 | METHOD FOR PREPARING BLOCK SLOW-RELEASE CONCRETE ADMIXTURE | 科之杰新材料集团有限公司 | 2020-07-02 | — | — | WO | claimed |
| US-10196424-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | claimed |
| CN-108719645-A | A kind of effective novel creep feed companion | 宁波科瑞特动物药业有限公司 | 2018-11-02 | — | — | CN | claimed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | claimed |
| EP-3169403-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics Inc. (US) | 2017-05-24 | — | — | EP | claimed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | claimed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | claimed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | claimed |